Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats

Sarah E. Maggio, Meredith A. Saunders, Thomas A. Baxter, Kimberly Nixon, Mark A. Prendergast, Guangrong Zheng, Peter Crooks, Linda P. Dwoskin, Rachel D. Slack, Amy H. Newman, Richard L. Bell, Michael T. Bardo

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, two-bottle choice), (2) nicotine alone (0.03 mg/kg/infusion, active vs. inactive lever), and (3) concurrent access to both EtOH and nicotine. Using this model, we examined the effects of (1) varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist with high affinity for the α4β2* subtype; (2) r-bPiDI, a subtype-selective antagonist at α6β2* nAChRs; and (3) (R)-modafinil, an atypical inhibitor of the dopamine transporter (DAT). Results: In phases 1 and 2, pharmacologically relevant intake of EtOH and nicotine was achieved. In the concurrent access phase (phase 3), EtOH consumption decreased while nicotine intake increased relative to phases 1 and 2. For drug pretreatments, in the EtOH access phase (phase 1), (R)-modafinil (100 mg/kg) decreased EtOH consumption, with no effect on water consumption. In the concurrent access phase, varenicline (3 mg/kg), r-bPiDI (20 mg/kg), and (R)-modafinil (100 mg/kg) decreased nicotine self-administration but did not alter EtOH consumption, water consumption, or inactive lever pressing. Conclusions: These results indicate that therapeutics which may be useful for smoking cessation via selective inhibition of α4β2* or α6β2* nAChRs, or DAT inhibition, may not be sufficient to treat EtOH and nicotine co-use.

Original languageEnglish
Pages (from-to)1439-1453
Number of pages15
JournalPsychopharmacology
Volume235
Issue number5
DOIs
StatePublished - May 1 2018

Bibliographical note

Funding Information:
Acknowledgements Supported by NIH grants R01AA025591, UL1TR000117, U19DA17548, P50DA05312, T32DA016176, and U24AA015512.

Funding Information:
Supported by NIH grants R01AA025591, UL1TR000117, U19DA17548, P50DA05312, T32DA016176, and U24AA015512. All testing procedures occurred during the light phase (7:00?am?7:00?pm) were in accordance with the NIH Guide for the Care and Use of Laboratory Animals (8th edition, 2011) and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky. The University of Kentucky holds a patent on r-bPiDI and a potential royalty stream to Dwoskin and Crooks may occur consistent with University of Kentucky policy.

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords

  • (R)-modafinil
  • Alcohol
  • Co-use
  • Ethanol
  • Nicotine
  • R-bPiDI
  • Varenicline

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats'. Together they form a unique fingerprint.

Cite this